Avadel pharmaceuticals announces final fda approval of lumryz™ (sodium oxybate) for extended-release oral suspension as the first and only once-at-bedtime oxybate for cataplexy or excessive daytime sleepiness in adults with narcolepsy

- granted orphan drug exclusivity through may 1, 2030 - -advanced commercial preparations on track; lumryz product availability expected in early june - - final approval supported by robust efficacy and safety data from pivotal phase 3 rest-on clinical trial - - management to host conference call today, may 1, 2023 at 4:00 p.m. et - dublin, may 01, 2023 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the u.s. food & drug administration (fda) has granted final approval to lumryz, an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (eds) in adults with narcolepsy.
AVDL Ratings Summary
AVDL Quant Ranking